In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy

Executive Summary

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

You may also be interested in...



Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions

The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.

Coming Of Age: Pharma’s Influencer Marketing Matures

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

Investment And Acquisition In Rare Diseases

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel